Ticker APVO – Aptevo Therapeutics – sales, description, marketcap – Tickerday.com

APVO

Aptevo Therapeutics

–

Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;

Marketcap: 24.76M; Volume: 6.49K; AvgVol 3m: 102.06K; Beta: 2.49;

Cost estimate:

P/E: –; EPS: -11.15; EPS growth quarter/prev quarter: 37.50%;

EPS growth this year: 54.10%; EPS growth past 5 years: 15.40%;

EPS ttm: -11.15;

P/S: 1.30; P/B: 2.80; P/Cashflow: ; P/FCF: ;

Sales: 18.51M; Sales growth quarter/prev quarter: -96.50%; Sales growth past 5 years: -6.60%;

Profitability:

Gross Margin: 45.50%; Profit Margin: ; Operating Margin: ;

ROA – return on assets: -48.20%; ROE – return on equity: -137.20%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;

Dividend: –; Dividend Yield (%): –;

Insider Ownership: 8.08%; Insider Transactions:0.00%;

Institutional Ownership: 35.00%; Institutional Transactions: 15.23%;

Data update: 07/10/2020.